1993 Volume 34 Issue 2 Pages 185-192
In vitro antifungal and antibacterial activities of a new thiocarbamate antifungal agent, liranaftate (M-732) previously designated piritetrate were tested using an agar plate dilution method in comparison with tolciclate and bifonazole.
Liranaftate exhibited the most potent antidermatophytic activity, for instance, Trichophyton rubrum: the growth of fresh clinical isolate and stock strains was inhibited at similar levels of MIC values, 0.009 to 0.078μg/ml and 0.004 to 0.078μg/ml, respectively. Liranaftate was also considerably potent against dimorphic fungi, Cryptococcus neoformans, and some other filamentous fungi. Some causative organisms of tinea versicolor were more sensitive to liranaftate than to tolciclate or bifonazole. Most Candida spp. and some bacteria including Nocardia spp. were resistant to liranaftate and tolciclate. It was confirmed that liranaftate was more potent in antifungal activity and had a broader spectrum than the two reference agents.
